IN2014CN04671A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04671A IN2014CN04671A IN4671CHN2014A IN2014CN04671A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A IN 4671CHN2014 A IN4671CHN2014 A IN 4671CHN2014A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A
- Authority
- IN
- India
- Prior art keywords
- compounds
- poly
- pharmaceutical compositions
- present
- treating diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- VZYRBVZOGGKAKY-UHFFFAOYSA-N 3-phenyl-2h-isoquinolin-1-one Chemical class C=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VZYRBVZOGGKAKY-UHFFFAOYSA-N 0.000 abstract 1
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190687 | 2011-11-25 | ||
| EP12161489 | 2012-03-27 | ||
| PCT/EP2012/073125 WO2013076090A1 (en) | 2011-11-25 | 2012-11-20 | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04671A true IN2014CN04671A (en:Method) | 2015-09-18 |
Family
ID=47227787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4671CHN2014 IN2014CN04671A (en:Method) | 2011-11-25 | 2012-11-20 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9422243B2 (en:Method) |
| EP (1) | EP2788328B1 (en:Method) |
| JP (1) | JP6106182B2 (en:Method) |
| KR (1) | KR20140097457A (en:Method) |
| CN (1) | CN103946214B (en:Method) |
| AU (1) | AU2012342562B2 (en:Method) |
| BR (1) | BR112014012031A2 (en:Method) |
| CA (1) | CA2856759A1 (en:Method) |
| CL (1) | CL2014001323A1 (en:Method) |
| EA (1) | EA027800B1 (en:Method) |
| ES (1) | ES2676068T3 (en:Method) |
| IN (1) | IN2014CN04671A (en:Method) |
| MX (1) | MX2014006015A (en:Method) |
| WO (1) | WO2013076090A1 (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN01875A (en:Method) | 2012-03-07 | 2015-07-03 | Cancer Res Inst Royal | |
| WO2015036759A1 (en) * | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| JP6663350B2 (ja) * | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| KR20180073685A (ko) | 2015-11-06 | 2018-07-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신경계 질환을 치료하기 위한, 무스카린성 수용체 4 (m4) 길항제로서의 n-[2-(1-벤질피페리딘-4-일)에틸]-4-(피라진-2-일)-피페라진-1-카르복스아미드 유도체 및 관련된 화합물 |
| JP2025522390A (ja) | 2022-06-15 | 2025-07-15 | アストラゼネカ・アクチエボラーグ | 癌を処置するための併用療法 |
| TW202508573A (zh) | 2023-05-11 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2444531A1 (en) * | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2002094790A1 (fr) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
| AU2003255149A1 (en) * | 2002-07-24 | 2004-02-09 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| WO2009104802A1 (en) * | 2008-02-22 | 2009-08-27 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2012
- 2012-11-20 EA EA201491026A patent/EA027800B1/ru not_active IP Right Cessation
- 2012-11-20 IN IN4671CHN2014 patent/IN2014CN04671A/en unknown
- 2012-11-20 CA CA2856759A patent/CA2856759A1/en not_active Abandoned
- 2012-11-20 KR KR1020147017409A patent/KR20140097457A/ko not_active Withdrawn
- 2012-11-20 MX MX2014006015A patent/MX2014006015A/es unknown
- 2012-11-20 CN CN201280057586.4A patent/CN103946214B/zh active Active
- 2012-11-20 AU AU2012342562A patent/AU2012342562B2/en not_active Ceased
- 2012-11-20 ES ES12791464.6T patent/ES2676068T3/es active Active
- 2012-11-20 JP JP2014542801A patent/JP6106182B2/ja active Active
- 2012-11-20 BR BR112014012031A patent/BR112014012031A2/pt not_active IP Right Cessation
- 2012-11-20 US US14/358,537 patent/US9422243B2/en active Active
- 2012-11-20 WO PCT/EP2012/073125 patent/WO2013076090A1/en active Application Filing
- 2012-11-20 EP EP12791464.6A patent/EP2788328B1/en active Active
-
2014
- 2014-05-20 CL CL2014001323A patent/CL2014001323A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1200166A1 (en) | 2015-07-31 |
| US9422243B2 (en) | 2016-08-23 |
| CN103946214B (zh) | 2016-08-17 |
| CA2856759A1 (en) | 2013-05-30 |
| JP6106182B2 (ja) | 2017-03-29 |
| EP2788328A1 (en) | 2014-10-15 |
| CN103946214A (zh) | 2014-07-23 |
| US20140336192A1 (en) | 2014-11-13 |
| CL2014001323A1 (es) | 2014-09-05 |
| EP2788328B1 (en) | 2018-01-31 |
| JP2014533709A (ja) | 2014-12-15 |
| EA027800B1 (ru) | 2017-09-29 |
| KR20140097457A (ko) | 2014-08-06 |
| AU2012342562B2 (en) | 2017-02-23 |
| MX2014006015A (es) | 2014-06-04 |
| BR112014012031A2 (pt) | 2017-05-30 |
| ES2676068T3 (es) | 2018-07-16 |
| EA201491026A1 (ru) | 2014-11-28 |
| WO2013076090A1 (en) | 2013-05-30 |
| AU2012342562A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX367425B (es) | Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1. | |
| PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| MX357502B (es) | Derivados de pirrolotriazinona. | |
| IN2014KN02601A (en:Method) | ||
| IN2014MN01875A (en:Method) | ||
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| SG10201805392YA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| IN2014CN04671A (en:Method) | ||
| MX2016001134A (es) | Derivados 1,3-disustituidos de ciclopentano. | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| MX2016001536A (es) | Derivados de urea de piperidinas. | |
| MX369393B (es) | Derivados de ftalazina. | |
| MX2016001934A (es) | Derivados de ciclopentilamina 3-sustituidos. | |
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors |